Lumida
/TXG
⌘K
10X Genomics Inc

10X Genomics Inc

TXG
$68.59USD+3.33%+2.21 today

MARKET CAP

8.9B

P/E (TTM)

FWD P/E

DAY RANGE

$67 – $70

52W RANGE

$11
$70

AI Summary

Stalk
StalkMedium

TXG is in a Stage 2 uptrend confirmed by steeply rising EMAs and an active Parabola pattern signaling aggressive trend acceleration. However, price is extreme overbought and extended well above the 9/20/50 EMAs, making immediate entries unfavorable. Medium-term bias remains bullish, with the preferred approach being to wait for pullbacks into the rising EMAs (9/20) for structural support and favorable risk/reward. A failure to hold these EMAs on a retracement would threaten the bullish stance.

  • EPS consensus revisions climbed 15.2% last three months, showing strong analyst sentiment
  • Collaborated with Lausanne University Hospital to advance cancer diagnostics
  • Q2 revenue dropped 12.7% YoY to $151M, hinting stagnation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$490.5M$516.4M$618.7M$610.8M$642.8M
YoY %+64.1%+5.3%+19.8%-1.3%+5.2%
P / Sales33.5x7.8x10.3x2.8x3.2x
EV / Sales32.7x7.8x10.1x2.6x2.8x
Gross Profit, Adj.$416.4M$396.0M$409.3M$414.5M$443.9M
YoY %+73.2%-4.9%+3.4%+1.3%+7.1%
Margin %84.9%76.7%66.2%67.9%69.1%
EV / Gross Profit38.5x10.2x15.2x3.8x4.1x
EBITDA, Adj.$-24.7M$-134.9M$-229.8M$-158.7M$-74.7M
YoY %+95.2%-447.2%-70.3%+31.0%+52.9%
Margin %-5.0%-26.1%-37.1%-26.0%-11.6%
EV / EBITDA-650.9x-29.8x-27.1x-10.0x-24.2x
EBIT$-52.3M$-167.9M$-265.3M$-194.6M$-61.0M
YoY %+90.2%-221.4%-58.0%+26.7%+68.7%
Margin %-10.7%-32.5%-42.9%-31.9%-9.5%
EV / EBIT-307.2x-24.0x-23.5x-8.2x-29.6x
Net Income$-58.2M$-166.0M$-255.1M$-182.6M$-43.5M
YoY %+89.3%-185.1%-53.7%+28.4%+76.2%
Net Margin-11.9%-32.1%-41.2%-29.9%-6.8%
EPS (GAAP)-$0.53-$1.46-$2.18-$1.52-$0.35
YoY %+90.1%-175.5%-49.3%+30.3%+77.0%